Hyperlipidemia – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23048IDB-L5

Select Item

Empower your strategies with our Hyperlipidemia – Drugs In Development, 2024 report and make more profitable business decisions.

Hyperlipidemia is a medical condition characterized by elevated levels of lipids (fats) in the blood. This includes high levels of cholesterol and triglycerides. It is a significant risk factor for cardiovascular diseases, such as atherosclerosis, coronary artery disease, and stroke. Hyperlipidemia can be caused by genetic factors, an unhealthy diet high in saturated fats and cholesterol, sedentary lifestyle, obesity, and certain medical conditions like diabetes mellitus. Diagnosis is typically made through blood tests measuring lipid levels. Treatment involves lifestyle modifications such as a healthy diet, regular exercise, and weight management. Medications, including statins, may be prescribed to lower lipid levels and reduce cardiovascular risk. Regular monitoring is essential for managing hyperlipidemia effectively.

The Hyperlipidemia drugs in development market research report provide comprehensive information on the therapeutics under development for Hyperlipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperlipidemia and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Hyperlipidemia
Key Targets
· Proprotein Convertase Subtilisin/Kexin Type 9; Apolipoprotein C III; 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase; Angiopoietin Related Protein 3; Peroxisome Proliferator Activated Receptor Alpha; Type 1 Angiotensin II Receptor; NPC1 Like Intracellular Cholesterol Transporter 1; Voltage Dependent L Type Calcium Channel; Diacylglycerol O Acyltransferase 1; and ATP Citrate Synthase
Key Mechanisms of Action
· Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor; Apolipoprotein C III Inhibitor; 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor; Angiopoietin Related Protein 3 Inhibitor; Peroxisome Proliferator Activated Receptor Alpha Agonist; NPC1 Like Intracellular Cholesterol Transporter 1 Inhibitor; Type 1 Angiotensin II Receptor Antagonist; Voltage Dependent L Type Calcium Channel Blocker; Thyroid Hormone Receptor Beta Agonist; and Angiopoietin Related Protein 4 Inhibitor
Key Routes of Administration
· Oral; Subcutaneous; Intravenous; and Parenteral
Key Molecule Types
· Small Molecule; Antisense RNAi Oligonucleotide; Monoclonal Antibody; Gene Therapy; Antisense Oligonucleotide; Biologic; Recombinant Protein; Monoclonal Antibody Conjugated; Synthetic Peptide; and Oligonucleotide
Major Companies
· Addpharma Inc; Kuhnil Pharmaceutical Co Ltd; Korea United Pharm Inc; Arrowhead Pharmaceuticals Inc; CVI Pharmaceuticals Ltd; Shanghai Minwei Biotechnology Co Ltd; Sirnaomics Ltd; Suzhou Ribo Life Sciences Co Ltd; Shenzhen Salubris Pharmaceuticals Co Ltd; and Shanghai Junshi Biosciences Co Ltd

Scope

  • Therapeutics in Development: Covering 133 molecules, with 120 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Hyperlipidemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Hyperlipidemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hyperlipidemia treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

89bio Inc
Addpharma Inc
Akeso Inc
Arrowhead Pharmaceuticals Inc
BCWorld Pharm Co Ltd
Beijing GeneCradle Technology Co Ltd
Beijing Mabworks Biotech Co Ltd
Beijing University of Chinese Medicine
Bio-Thera Solutions Ltd
BioRestorative Therapies Inc
CannaLean Biotechs Ltd
Cardax Inc
Celltrion Inc
Centeer BioTherapeutics Ltd Co
Chinese Academy of Medical Sciences and Peking Union Medical College
Chinese Academy of Sciences
Chong Kun Dang Pharmaceutical Corp.
Columbia University
CVI Pharmaceuticals Ltd
Daewon Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Dalian Wista Pharmaceutical Co Ltd
DongKoo Bio & Pharma Co Ltd
Eddingpharm Inc
Eli Lilly and Co
EmendoBio Inc
Esperion Therapeutics Inc
FUDAN University
GENUONE Sciences Inc
Golden Biotechnology Corp
Guangzhou Jiayue Pharmaceutical Technology Co Ltd
Handok Inc
Hanmi Pharmaceuticals Co Ltd
Helmholtz Center Munich German Research Center for Health and Environment GmbH
HighTide Therapeutics Inc
HK inno.N Corp
Huons Co Ltd
Ildong Pharmaceutical Co Ltd
Inovio Pharmaceuticals Inc
Inversago Pharma Inc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Korea United Pharm Inc
Kowa Co Ltd
Kuhnil Pharmaceutical Co Ltd
Kyttaro Ltd
Liaoning University of Traditional Chinese Medicine
Liid Pharmaceuticals Inc
Lipigon Pharmaceuticals AB
LipimetiX Development Inc
Luye Pharma Group Ltd
Marea Therapeutics
MediciNova Inc
Mochida Pharmaceutical Co Ltd
NorthSea Therapeutics BV
NovalGen Ltd
Novartis AG
Novo Nordisk AS
Nubiyota LLC
NuSirt Biopharma Inc
OrsoBio Inc
Osaka University
Peking University
Purpose Bio Inc
Regeneron Pharmaceuticals Inc
Rivus Pharmaceuticals Inc
Runjia (Suzhou) Pharmaceutical Technology Co Ltd
Saliogen Therapeutics Inc
Sequor Pharmaceuticals LLC
Shanghai Junshi Biosciences Co Ltd
Shanghai Minwei Biotechnology Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Sirnaomics Ltd
SUNY Downstate Medical Center
Suzhou Ribo Life Sciences Co Ltd
Sveikatal Inc
The United Laboratories International Holdings Ltd
University College of Medical Sciences
University of Cincinnati
University of Wisconsin Madison
Viking Therapeutics Inc
Visirna Therapeutics HK Ltd
Waterstone Pharmaceuticals (Wuhan) Ltd
Yooyoung Pharm Co Ltd
Zhejiang Jingxin Pharmaceutical Co Ltd
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Hyperlipidemia reports
Pharmaceuticals
New
Human Immunodeficiency Virus (HIV) Major Markets: Disease Management, Epidemiology, Pipeline…
$17,995 | March 2026
Pharmaceuticals
New
Catalyst Monitor: Q2 2026 Outlook
$1,870 | March 2026
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q1 2026
$2,950 | March 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hyperlipidemia – Drugs In Development, 2024 in real time.

  • Access a live Hyperlipidemia – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more